膀胱内注射A型肉毒毒素与联合药物治疗难治性膀胱过度活动症的随机对照试验
单中心开放标签随机试验纳入74例经尿动力学确诊逼尿肌过度活动且单药治疗至少2个月仍持续症状的患者,随机接受膀胱内注射onabotulinumtoxinA 100 U或索利那新5 mg联合米拉贝隆25 mg治疗。12周时两组急迫性尿布发作中位数均降至每24小时2.0次,组间平均差异-0.1(95%CI:-1.5至1.4;
要点
- 膀胱内注射onabotulinumtoxinA与索利那新联合米拉贝隆在难治性OAB中疗效相当。
- 联合药物治疗组口干、便秘和视物模糊等不良事件显著更多。
- 对全身抗胆碱能效应敏感或偏好非每日干预者,注射治疗是合适选择。
核心结论
- 膀胱内注射onabotulinumtoxinA与联合药物治疗均能改善女性难治性膀胱过度活动症症状,两者疗效无显著差异。
- onabotulinumtoxinA安全性更优,适合对全身抗胆碱能效应敏感或偏好非每日干预的患者。
研究设计与样本
- 单中心、开放标签、随机对照试验,纳入74例经尿动力学确诊逼尿肌过度活动且至少2个月单药治疗仍持续症状的患者,66例完成研究(每组33例)。
- 干预组接受膀胱内注射onabotulinumtoxinA 100 U,对照组接受索利那新5 mg联合米拉贝隆25 mg治疗。
- 基线及12周评估排尿参数、不良事件及患者报告结局(泌尿生殖窘迫量表、失禁影响问卷、膀胱过度活动症症状评分)。
主要发现
- 两组在尿频、夜尿、急迫性尿失禁及生活质量指标上均有改善,组间无显著差异。
关键数值与推荐
- 纳入标准:尿动力学确诊逼尿肌过度活动,且至少2个月单药治疗仍持续症状。
- onabotulinumtoxinA剂量为100 U膀胱内注射;联合药物为索利那新5 mg加米拉贝隆25 mg。
临床怎么用
- 对难治性OAB女性,膀胱内注射onabotulinumtoxinA 100 U可作为与联合药物疗效相当的选项。
- 对全身抗胆碱能效应敏感或希望非每日干预的患者,可优先考虑onabotulinumtoxinA注射。
- 选择联合药物治疗时需关注口干、便秘和视物模糊等不良事件。
局限性
- 单中心、开放标签设计,样本量较小(74例入组,66例完成)。
- 随访至12周,未报告长期疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We investigated whether intradetrusor onabotulinumtoxinA injection demonstrates superior efficacy and fewer side effects compared with combined pharmacotherapy in patients with refractory overactive bladder. MATERIALS AND METHODS: In this single-center, open-label, randomized trial, patients with urodynamically confirmed detrusor overactivity and persistent symptoms despite at least 2 months of single pharmacotherapy were randomized to receive onabotulinumtoxinA injection (100 U) or combined pharmacotherapy with solifenacin 5 mg and mirabegron 25 mg. Assessments at baseline and 12 weeks included voiding parameters, adverse events, and patient-reported outcomes using the Urogenital Distress Inventory, Incontinence Impact Questionnaire, and the Overactive Bladder Symptom Score. RESULTS: Of 74 patients enrolled, 66 completed the study (33 per group). Both treatments reduced urgency episodes to a median of 2.0 per 24 hours at 12 weeks. The mean difference between groups was -0.1 (95% CI: -1.5 to 1.4; P = .925), indicating no significant difference. Improvements in urinary frequency, nocturia, urge incontinence, and quality-of-life measures were observed in both groups, without significant differences. However, adverse effects such as dry mouth, constipation, and blurred vision were significantly more common with pharmacotherapy (all P < .05). CONCLUSIONS: Both intradetrusor onabotulinumtoxinA and combined pharmacotherapy improved symptoms in women with refractory overactive bladder. OnabotulinumtoxinA demonstrated a more favorable safety profile and represents an appropriate option for patients sensitive to systemic anticholinergic effects or preferring nondaily interventions. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05968885.
引用
- Hsieh MH, Hwang JC, Su TH, et al. The Efficacy and Safety Between Intradetrusor OnabotulinumtoxinA Injection and Combined Pharmacotherapy in Patients With Refractory Overactive Bladder: A Randomized Controlled Trial. J Urol. 2025. PMID: 40590342. doi:10.1097/JU.0000000000004660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。